SCHEMBL3349306

SCHEMBL3349306

CCC(NCC(C)C)NC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAPT P10636 2/20 0.35
ALDH1A1 P00352 3/20 0.32
MMP1 P03956 2/20 0.32
MMP8 P22894 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
EPHX1 P07099 1/20 0.32
MME P08473 1/20 0.32
ACE P12821 1/20 0.32
CPA1 P15085 1/20 0.32
ACE2 Q9BYF1 1/20 0.32
MMP2 P08253 1/20 0.31
MMP3 P08254 1/20 0.31
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31
TAS1R2 Q8TE23 1/20 0.31
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1966631 0.80 CYP2D6 (0.34) CYP2D6CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL4667011 0.77 ADH1B (0.33) CYP2D6CYP2C19
SCHEMBL2433388 0.75 MMP1 (0.33) CYP2D6CYP2C19MAPTALDH1A1MMP1
SCHEMBL5439835 0.74 CYP2D6 (0.47) CYP2D6CYP2C19MAPTALDH1A1MMP1
SCHEMBL1962473 0.72 ADH1B (0.30)
SCHEMBL23795389 0.72 PTGS1 (0.33) ALDH1A1
SCHEMBL564048 0.70 MAPT (0.46) CYP2D6CYP2C19MAPTALDH1A1SMN1; SMN2
SCHEMBL21322181 0.70 MAPT (0.46) CYP2D6CYP2C19MAPTALDH1A1SMN1; SMN2
SCHEMBL3154720 0.68 ALDH1A1 (0.55) CYP2D6CYP2C19ALDH1A1MMEACE
SCHEMBL28775547 0.68 ALDH1A1 (0.55) CYP2D6CYP2C19ALDH1A1MMEACE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-7498436-B2 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY LLC (US) 2009-03-03 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7176242-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2007-02-13 US disclosed
US-20060106256-A1 Substituted hydroxyethylamines PHARMACIA & UPJOHN COMPANY 2006-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT CYP2D6 1759/4885CYP2C19 1374/4885MAPT 6/4885
US-20060106256-A1 Substituted hydroxyethylamines HNMT, PNMT, BCHE CYP2D6 308/4885CYP2C19 430/4885MAPT 43/4885
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP CYP2D6 4009/4885CYP2C19 4077/4885MAPT 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.